Peptides Research Hub

Clinical Trial Identifier

NCT01272232

Liraglutide 3.0 mg, part of the SCALE program.

Trial details

Identifier
NCT01272232
Sponsor
Novo Nordisk
Asset
Liraglutide 3.0 mg
Program
SCALE
Phase
Phase III
Therapeutic area
Obesity / Weight Management

Program context

SCALE

Approximately 8.0% mean body-weight reduction in the SCALE Obesity and Prediabetes trial versus 2.6% with placebo at 56 weeks; approximately 6.0% in adults with T2DM; significant weight loss maintenance in SCALE Maintenance; and modest improvements in sleep apnea severity in SCALE Sleep Apnea.

Read the SCALE spotlight

Trial-level analysis lives in the program spotlight linked above. For the canonical registry record, including study design, eligibility, locations, and posted results, visit ClinicalTrials.gov.